

August 7, 2024

News Release

Company: Olympus Corporation
Stefan Kaufmann, Director, Representative Executive Officer, President and CEO
(Code: 7733, Prime, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-42-642-2111

Notice Concerning Change of Executive Officers

Olympus Corporation ("Olympus") hereby announces that the Board of Directors held today has decided to appoint the executive officers as described below.

1. Reason for change

(1) John de Csepel

It is imperative to strengthen the Medical and Scientific Affairs function, which provides clinical and medical expertise to healthcare professionals, in order to develop and deploy our medical business strategy.

In addition to his role as a surgeon, John de Csepel has extensive experience serving as a leader of Medical Affairs and global Chief Medical Officer. We believe that his exceptional expertise and leadership will bridge medical fields with our business and enhance the presence of MSA throughout our organization.

(2) Neil Boyden Tanner

As we strive to enhance our corporate value as a global MedTech company, it is crucial to bolster our presence in the medical and healthcare industry. Our legal team has been instrumental in the development and implementation of our global strategy, operating with the highest standards, and has established a globally unified legal function and strengthened global and cross-functional collaboration.

Neil Boyden Tanner has an extensive background in the global healthcare industry and has experience in crisis management, corporate governance, major acquisitions, and working globally, including in Japan. We believe that he will contribute to reinforcing holistic enterprise risk management and maximizing our corporate value.

2. Names and job titles of newly appointed executive officers

Name	Current job titles	New job titles after October 1, 2024
John de Csepel	Chief Medical Officer	Executive Officer and Chief Medical Officer
Neil Boyden Tanner	Global General Counsel	Executive Officer and Global General Counsel

3. Career summary of newly appointed executive officers

(1) John de Csepel

Date of Birth:	July 21, 1964	
Career summary:	August 1991	Medical Doctor, Georgetown University School of Medicine (graduated in 1995)
	July 1995	General Surgery Resident, Mount Sinai School of Medicine
	July 2000	Laparoscopic Surgery Fellow, Mount Sinai School of Medicine
	October 2001	Chief, Division of Minimally Invasive Surgery, Saint Vincent's Hospital, Assistant Professor of Surgery, New York Medical College
	June 2006	War Surgeon, Doctors Without Borders
	January 2007	Vice President, Medical Affairs, BARRX Medical (acquired by Covidien plc)
	February 2013	Chief Medical Officer & Vice President, Surgical Innovations, Covidien plc (acquired by Medtronic plc)
	May 2015	Trauma Surgeon, Mount Sinai Elmhurst Faculty Practice, Clinical Instructor of Surgery, Mount Sinai School of Medicine (present)
	May 2018	Chief Medical Officer & Vice President, Minimally Invasive Therapies Group, Medtronic plc
	November 2020	Chief Medical Officer & Vice President, Americas Region, Medtronic plc
	October 2022	Chief Medical Officer & Vice President, Global Regions, Medtronic plc
	October 2023	Chief Medical Officer, Olympus Corporation (present)
October 2024	Executive Officer (Plan) and Chief Medical Officer, Olympus Corporation	
Number of shares of the Company held (Note 2) (Of which, the number of shares to be delivered under the stock compensation plan):		0 (0)

(2) Neil Boyden Tanner

Date of Birth:	May 22, 1971	
Career summary:	August 1997	Joined Pepper Hamilton and Scheetz LLP (currently Troutman Pepper Hamilton Sanders LLP)
	June 2005	Associate General Counsel, International, Aramark
	December 2009	General Counsel, Cigna Global Health Benefits (formerly Cigna International Expatriate Benefits), The Cigna Group (formerly Cigna Corporation)
	December 2010	Acting Chief Compliance Officer International, The Cigna Group (formerly Cigna Corporation)
	May 2014	Vice President, Chief Counsel for U.S. Business Law and Corporate Secretary, The Cigna Group (formerly Cigna Corporation)
	November 2018	Senior Vice President, Chief Counsel for U.S. Business Law and Corporate Secretary, The Cigna Group (formerly Cigna Corporation)
	December 2018	General Counsel, International Markets, The Cigna Group (formerly Cigna Corporation)
	January 2022	Senior Vice President and General Counsel for Strategy, Finance and International Markets, The Cigna Group (formerly Cigna Corporation)
	January 2024	Joined Olympus Corporation
	April 2024	Global General Counsel, Olympus Corporation (Present)
October 2024	Executive Officer (Plan) and Global General Counsel, Olympus Corporation	
Licensed attorney:	Commonwealth of Pennsylvania (1997) State of New Jersey (1998) District of Columbia (1998)	
Number of shares of the Company held (Of which, the number of shares to be delivered under the stock compensation plan):		0 (0)

● Other positions, etc.

Career summary:	July 2001	Board of Directors (Present) and Past President, British American Business Council of Greater Philadelphia
	June 2012	Board of Trustees, Vice Chair, American University of Rome (Present)
	January 2013	Eisenhower Fellow

(Note) “Number of shares of the Company held” indicates the number of shares held as of March 31, 2024. It also includes the number of shares each candidate hold through the Officers’ Shareholding Association of the Company, his/her own equity interest held though a company managing stock compensation of the Company as well as the number of shares to be delivered under the stock compensation plan.

4. New management team from October 1, 2024

The executive officers are stated by the alphabetical order of last name excluding the representative officers.

Yasuo Takeuchi	Director, Representative Executive Officer, and Executive Chairman and ESG Officer
Stefan Kaufmann	Director, Representative Executive Officer, President and Chief Executive Officer
John de Csepel	Executive Officer and Chief Medical Officer
Frank Drewalowski	Executive Officer and Endoscopic Solutions Division Head
Tatsuya Izumi	Executive Officer and Chief Financial Officer
Gabriela Kaynor	Executive Officer and Chief Strategy Officer
Tetsuo Kobayashi	Executive Officer and Chief Manufacturing and Supply Officer
Seiji Kuramoto	Executive Officer and Therapeutic Solutions Division Head
Shigeto Ohtsuki	Executive Officer and Chief Human Resources Officer
André Roggan	Executive Officer and Chief Technology Officer
Boris Shkolnik	Executive Officer and Chief Quality Officer
Neil Boyden Tanner	Executive Officer and Global General Counsel